INFLUENCE OF GESTODENE AND DESOGESTREL AS COMPONENTS OF LOW-DOSE ORAL-CONTRACEPTIVES ON THE PHARMACOKINETICS OF ETHINYL ESTRADIOL (EE2), ON SERUM CBG AND ON URINARY CORTISOL AND 6-BETA-HYDROXYCORTISOL

被引:27
作者
HAMMERSTEIN, J
DAUME, E
SIMON, A
WINKLER, UH
SCHINDLER, AE
BACK, DJ
WARD, S
NEISS, A
机构
[1] UNIV MARBURG KLINIKUM, ZENTRUM FRAUENHEILKUNDE & GEBURTSHILFE, GYNAKOL ENDOKRINOL & REPROD ABT, MARBURG, GERMANY
[2] UNIV ESSEN GESAMTHSCH, ZENTRUM FRAUENHEILKUNDE, GYNAKOL INSBESONDERE GYNAKOL ONKOL ABT, W-4300 ESSEN 1, GERMANY
[3] UNIV LIVERPOOL, DEPT PHARMACOL & THERAPEUT, LIVERPOOL L69 3BX, ENGLAND
[4] UNIV INNSBRUCK, INST BIOSTAT & DOKUMENTAT, A-6020 INNSBRUCK, AUSTRIA
关键词
D O I
10.1016/0010-7824(93)90043-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A randomized controlled clinical trial was undertaken over a 6-month treatment period with two low-dose combined oral contraceptives (OC) to investigate whether the metabolism and elimination of ethinyl estradiol (EE2) is differently influenced by the two progestational components gestodene (G) and desogestrel (D), an issue which has been very controversial recently. The two formulations contained 30 mug EE2 each,together with either 75 mug G or 150 mug D. Of the 40 young women recruited for each formulation, 31 of each group were available for statistical evaluation. The pharmacokinetics of serum EE2 were studied on day 1, 10 and 21 of cycle 1, 3 and 6. There were no significant differences between the two groups in any cycle with respect to parameters measured. This was true for the distinct intracyclical rise in the mean EE2 serum levels from day 1 to day 10 and the smaller further increase between day 10 and day 21, with no change in this respect between the cycles studied. Respective changes were seen with regard to the area under the EE2 serum concentration curve up to 4 and 24 hours (AUC0-4 and AUC0-24), c(max) and t(max) Of serum EE2. The estrogen-dependent corticoid-binding globulin (CBG) increased simililarly in the two groups intracyclically and slightly also intercyclically at all times tested. Except for the first treatment cycle, urinary excretion of cortisol and 6beta-hydroxycortisol displayed a tendency to lower values intracyclically as well as intercyclically, again with no differences between the two groups. Also, the 6beta-hydroxycortisol-to-cortisol ratio was not different between the groups, showing a slight tendency to rise from about 4 at the beginning of the medication to around 5.5 at the end of the 6th treatment cycle in both groups. It is concluded that G and D as components of low-dose OCs exert comparable effects on the metabolism and elimination of EE2.
引用
收藏
页码:263 / 281
页数:19
相关论文
共 20 条
[1]   INVESTIGATION OF THE PHARMACOKINETICS OF ETHYNYLESTRADIOL IN WOMEN USING RADIOIMMUNOASSAY [J].
BACK, DJ ;
BRECKENRIDGE, AM ;
CRAWFORD, FE ;
MACIVER, M ;
ORME, MLE ;
ROWE, PH ;
WATTS, MJ .
CONTRACEPTION, 1979, 20 (03) :263-273
[2]  
BACK DJ, 1991, ADV CONTRACEPT S3, V7, P164
[3]   HUMAN CORTICOSTEROID BINDING GLOBULIN [J].
BRIEN, TG .
CLINICAL ENDOCRINOLOGY, 1981, 14 (02) :193-212
[4]   GROUP COMPARISON OF SERUM ETHINYL ESTRADIOL, SHBG AND CBG LEVELS IN 83 WOMEN USING 2 LOW-DOSE COMBINATION ORAL-CONTRACEPTIVES FOR 3 MONTHS [J].
DIBBELT, L ;
KNUPPEN, R ;
JUTTING, G ;
HEIMANN, S ;
KLIPPING, CO ;
PARIKKAOLEXIK, H .
CONTRACEPTION, 1991, 43 (01) :1-21
[5]   INHIBITION OF ORAL-CONTRACEPTIVE STEROID METABOLIZING ENZYMES BY STEROIDS AND DRUGS [J].
GUENGERICH, FP .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) :2159-2163
[6]   COMPARISON OF SERUM ETHINYL ESTRADIOL, SEX-HORMONE-BINDING GLOBULIN, CORTICOID-BINDING GLOBULIN AND CORTISOL-LEVELS IN WOMEN USING 2 LOW-DOSE COMBINED ORAL-CONTRACEPTIVES [J].
HUMPEL, M ;
TAUBER, U ;
KUHNZ, W ;
PFEFFER, M ;
BRILL, K ;
HEITHECKER, R ;
LOUTON, T ;
STEINBERG, B .
HORMONE RESEARCH, 1990, 33 (01) :35-39
[7]   INVESTIGATIONS OF PHARMACOKINETICS OF ETHINYLESTRADIOL TO SPECIFIC CONSIDERATION OF A POSSIBLE 1ST-PASS EFFECT IN WOMEN [J].
HUMPEL, M ;
NIEUWEBOER, B ;
WENDT, H ;
SPECK, U .
CONTRACEPTION, 1979, 19 (04) :421-432
[8]   PHARMACOKINETICS AND PHARMACODYNAMICS OF ORAL-CONTRACEPTIVE STEROIDS - FACTORS INFLUENCING STEROID-METABOLISM [J].
JUNGHOFFMANN, C ;
KUHL, H .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1990, 163 (06) :2183-2197
[9]   INTERACTION WITH THE PHARMACOKINETICS OF ETHINYLESTRADIOL AND PROGESTOGENS CONTAINED IN ORAL-CONTRACEPTIVES [J].
JUNGHOFFMANN, C ;
KUHL, H .
CONTRACEPTION, 1989, 40 (03) :299-312
[10]   PLASMA-LEVELS OF ETHINYLESTRADIOL (EE) DURING CYCLIC TREATMENT WITH COMBINED ORAL-CONTRACEPTIVES [J].
KAUFMAN, JM ;
THIERY, M ;
VERMEULEN, A .
CONTRACEPTION, 1981, 24 (05) :589-602